NR1H4
Bile acid receptor
As of the edition of 20 October 2026, NR1H4 (bile acid receptor, UniProt Q96RI1) has 13 drugs tested at it and 17 companies on the list, 4 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q96RI1
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 92
- Disease areas
- Digestive system; Nutrition and metabolism; Inherited and neonatal; Cancer; Pregnancy and women's health; Urinary and reproductive; Infections; Hormones
- Registered trials of its drugs
- 195
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 2 |
| Went quiet | 2 |
| Stopped | 4 |
| Status not established | 2 |
| Total | 13 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ursodiol | Marketed | Phase 4 | none listed |
| Obeticholic acid | Marketed | Phase 4 | Ends 2033 |
| Chenodiol | Marketed | Phase 4 | none listed |
| Cilofexor | Stopped | Phase 3 | none listed |
| EDP 305 | Stopped | Phase 2 | none listed |
| Tropifexor | Stopped | Phase 2 | none listed |
| ASC42 | Active | Phase 2 | none listed |
| HEC96719 | Active | Phase 2 | none listed |
| Vonafexor | Stopped | Phase 2 | none listed |
| Nidufexor | Went quiet | Phase 2 | none listed |
| TERN-101 | Status not established | Phase 2 | none listed |
| EDP-297 | Went quiet | Phase 1 | none listed |
12 of 13 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Route B | 3 |
| Engaged | 4 |
| Undetermined | 6 |
| Total on the list | 17 |
| Company | Route |
|---|---|
| Gilead Sciences | Route A |
| Novartis | Route A |
| Teva | Route B |
The other 14 companies at NR1H4
In the product17 companies in all; 14 are not named here, and no score is.
See the 17 companies at NR1H4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.